Biphenylcarboxylic acid compounds, their preparation methods and pharmaceutical uses
By preparing biphenyl carboxylic acid compounds and their salts, the problems of poor tolerance and insufficient inhibitory activity of existing URAT1 inhibitors have been solved, achieving a strong URAT1 inhibitory effect, which can be applied to the treatment of hyperuricemia and gout.
Patent Information
- Application Number
- CN202211251941.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-10-13
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2042-10-13
AI Technical Summary
Existing URAT1 inhibitors, such as probenecid and benzbromarone, have problems with poor tolerability and numerous toxic side effects. Furthermore, the dosage of existing drugs used in clinical practice is too high or their inhibitory activity is insufficient, resulting in poor treatment effects for hyperuricemia and gout.
A biphenyl carboxylic acid compound and its physiologically acceptable salt are provided. An intermediate is generated by reacting an aryl cyano compound with hydroxylamine hydrochloride and sodium carbonate under catalysis, followed by reaction with biphenyl anhydride to prepare the target compound. This compound is used to prepare URAT1 inhibitors for the prevention or treatment of hyperuricemia and gout.
This compound exhibits significant URAT1 inhibition, with some compounds showing stronger in vitro inhibitory activity than clinical counterparts such as benzbromarone, suggesting its potential application in the treatment of hyperuricemia and gout.
Smart Images

Figure CN117886773B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medicinal chemistry, specifically relating to biphenyl carboxylic acid compounds of general formula (I) and their physiologically acceptable salts, the use of these compounds in the preparation of urate transporter 1 (URAT1) inhibitors, their use in the preparation of medicaments for the prevention or treatment of URAT1-related diseases, methods of using them for treatment, and pharmaceutical compositions containing said compounds. Background Technology
[0002] Gout is an inflammatory joint disease caused by the deposition of uric acid monosodium urate in the joints and peripheral tissues. Hyperuricemia, resulting from increased uric acid production and / or decreased excretion, is a direct cause of gout. Hyperuricemia is also closely related to various diseases such as metabolic syndrome, hypertension, diabetes, and cardiovascular disease.
[0003] Urate-lowering therapy (ULT) is the main strategy for treating hyperuricemia and chronic gout. Currently, ULT is mainly divided into three categories: (1) xanthine oxidase (XOD) inhibitors, which inhibit uric acid production; (2) urate transporter 1 (URAT1) inhibitors, which promote uric acid excretion; and (3) uricase, which converts uric acid into water-soluble substances. The pathogenesis of approximately 90% of hyperuricemia patients is related to reduced uric acid excretion, and URAT1 is a clinically validated important target for regulating uric acid reabsorption and promoting uric acid excretion. Therefore, URAT1 inhibitors are important ULT therapies. Currently, the URAT1 inhibitors approved for marketing worldwide include benzbromarone, probenecid, retinoic acid, and dotinurad. In my country, only probenecid and benzbromarone are used clinically. However, probenecid and benzbromarone have problems such as poor tolerability and numerous toxic side effects. Recinard, launched at the end of 2015, is used in combination with the XOD inhibitor allopurinol to treat hyperuricemia and chronic gout. Its inhibitory activity against URAT1 is relatively weak, and the clinical dosage used is high (200 mg / day). Dotinurad was launched in Japan in January 2020, but its clinical application is still relatively limited.
[0004] In recent years, with changes in people's dietary structure and the acceleration of population aging, the incidence of gout has been rising continuously, becoming an undeniable public health problem. Currently, there are few clinically available treatments, and each has its own limitations. URAT1 is a clinically validated effective target for uric acid-lowering therapy; therefore, researching novel URAT1 inhibitors has significant practical implications and market potential. Summary of the Invention
[0005] The present invention aims to provide a biphenyl carboxylic acid compound as shown in general formula (I).
[0006] Another object of the present invention is to provide a method for preparing biphenyl carboxylic acid compounds represented by general formula (I).
[0007] Another object of the present invention is to provide the use of the biphenyl carboxylic acid compounds represented by general formula (I) in the preparation of URAT1 inhibitors, and in the preparation of medicaments for the prevention or treatment of URAT1-related diseases.
[0008] The technical problem solved by the present invention is to provide a biphenyl carboxylic acid compound of formula (I) and its physiologically acceptable salt, its preparation method, pharmaceutical composition and use in the preparation of URAT1 inhibitors, and its use in the preparation of a compound for the prevention and / or treatment of hyperuricemia and gout.
[0009] To solve the technical problem of this invention, the technical solution adopted by this invention is to provide biphenyl carboxylic acid compounds represented by general formula (I) and their physiologically acceptable salts:
[0010]
[0011] Ar is selected from substituted or unsubstituted phenyl, substituted or unsubstituted pyridyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted naphthyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted thiopheneyl, and substituted or unsubstituted furanyl; the substituent is a monosubstituted or polysubstituted group, each independently selected from hydrogen, halogen, C 1- C3 alkyl, C 1- C3 alkoxy group.
[0012] Another technical solution of the present invention is to provide a compound represented by general formula (IA) and its physiologically acceptable salt:
[0013]
[0014] R1 or R2 is independently selected from hydrogen, halogen, C 1- C3 alkyl, C 1- C3 alkoxy group.
[0015] Another technical solution of the present invention is to provide a compound represented by general formula (IB) and its physiologically acceptable salt:
[0016]
[0017] R3 is selected from hydrogen, halogens, and C. 1- C3 alkyl, C 1- C3 alkoxy group;
[0018] Another technical solution of the present invention is to provide the indicated compound and its physiologically acceptable salt, characterized in that the compound is selected from:
[0019]
[0020]
[0021] Another technical solution of the present invention is to provide a method for preparing a compound represented by general formula (I), characterized by comprising the following steps:
[0022] The aryl cyano compound Ar-CN reacts with hydroxylamine hydrochloride under sodium carbonate catalysis to give intermediate I-1, which then reacts with biphenyl anhydride under sodium hydroxide catalysis to generate target compound I;
[0023]
[0024] The definition of Ar is the same as in claims 1-4.
[0025] To prepare a pharmaceutical preparation, a compound of general formula (I) may be mixed with a suitable pharmaceutical carrier substance, flavoring agent, flavoring agent and pigment by a known method and made into a tablet or coated tablet, or suspended or dissolved in water or oil with other additives.
[0026] The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I) and a pharmaceutically acceptable carrier in an effective dose of the drug.
[0027] Pharmacological studies have shown that the compound of general formula (I) of the present invention has URAT1 inhibitory activity and can be used to treat URAT1-related diseases such as hyperuricemia and gout.
[0028] The compounds of this invention can be administered orally or via non-gastrointestinal routes. Oral administration may include tablets, capsules, or coated formulations; non-gastrointestinal dosage forms include injections and suppositories. These formulations are prepared according to methods well known to those skilled in the art. The excipients used in the manufacture of tablets, capsules, and coated formulations are conventionally used adjuvants, such as starch, gelatin, gum arabic, silica, and polyethylene glycol; solvents used in liquid dosage forms include, for example, water, ethanol, propylene glycol, and vegetable oils such as corn oil, peanut oil, and olive oil. Formulations containing the compounds of this invention may also contain other adjuvants, such as surfactants, lubricants, disintegrants, preservatives, flavoring agents, and colorants.
[0029] Beneficial technical effects:
[0030] URAT1 inhibitors are important uric acid-lowering drugs used clinically. The compounds involved in this invention have significant URAT1 inhibitory activity. Among them, some compounds exhibit stronger in vitro URAT1 inhibitory activity compared to benzbromarone, a similar clinical product. Detailed Implementation
[0031] The invention will be further described below with reference to the embodiments, but these embodiments do not limit the scope of the invention.
[0032] All reagents and solvents used in the synthesis experiments were purchased commercially and used directly without processing. Anhydrous solvents were commercially available ultra-dry solvents, and the mixing ratios were by volume. All reaction monitoring was performed using GF-254 thin-layer silica gel plates, and column chromatography separation was performed using 200-300 mesh silica gel. 1 H-NMR was acquired using a Varian Mercury 400-MHz NMR spectrometer. Chemical shifts (δ) are given in parts per million (ppm), with TMS as the internal standard, and coupling constants in Hertz (Hz).
[0033] Example 1: TM-1
[0034]
[0035] (1) Preparation of intermediate IA-1
[0036]
[0037] 4-Cyanopyridine (0.521 g, 5 mmol), hydroxylamine hydrochloride (0.521 g, 6 mmol), and sodium carbonate (1.06 g, 10 mmol) were added to 30 mL of a 4:1 mixture of ethanol and water. The reaction mixture was heated to 70 °C and reacted for 6 h. The reaction was monitored by TLC until complete. After removing the solvent under reduced pressure, the mixture was separated by column chromatography (petroleum ether-ethyl acetate = 3:1) to give intermediate IA-1, 0.63 g, yield: 92%. 1 H NMR (400MHz, DMSO-d6) δ10.04(s,1H),8.61–8.53(m,2H),7.67–7.61(m,2H),6.00(s,2H).
[0038] (2) Preparation of target TM-1
[0039]
[0040] Intermediate IA-1 (0.411 g, 3 mmol) and biphenyl anhydride (0.673 g, 3 mmol) were added to 15 mL of dimethyl sulfoxide and reacted at room temperature for 3 h. Sodium hydroxide (0.240 g, 6 mmol) was added and reacted at room temperature for 3 h. The reaction was monitored by TLC until it was complete. 100 mL of water was added to the reaction solution and the pH was slowly adjusted to 4-5 with 1 N hydrochloric acid aqueous solution. A solid precipitated, filtered, dried, and recrystallized from ethyl acetate to give 0.67 g of the target compound TM-1, yield: 65%, white solid. 1 H NMR (400MHz, DMSO-d6) δ12.56(s,1H),8.80–8.75(m,2H),8.20(dd,J=7.8,1.3Hz,1H),7.96(dd,J=7.8,1.3Hz,1H),7.81–7.76(m,2H),7.73 (td,J=7.8,1.3Hz,1H),7.64(tt,J=7.8,1.3Hz,2H),7.56(td,J=7.8,1.3Hz,1H),7.41(dd,J=7.8,1.3Hz,1H),7.30(dd,J=7.8,1.3Hz,1H).
[0041] Example 2: TM-2
[0042]
[0043] The synthesis method is similar to that of TM-1, except that 2-bromo-4-cyanopyridine is used instead of 4-cyanopyridine in the first step, and the yield of the last step is 39%, a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.57(s,1H),8.59(d,J=5.0Hz,1H),8.21(d,J=7.7Hz,1H),7.96(d,J=7.7Hz,1H),7.93(s,1H),7.84(d, J=5.0Hz,1H),7.74(t,J=7.7Hz,1H),7.64(t,J=7.7Hz,2H),7.56(t,J=7.7Hz,1H),7.41(d,J=7.7Hz,1H),7.29(d,J=7.7Hz,1H).
[0044] Example 3: TM-3
[0045]
[0046] The synthesis method is similar to that of TM-1, except that the first step uses 2-chloro-4-cyanopyridine instead of 4-cyanopyridine, and the final step yields 63% in a white solid. 1H NMR (400MHz, DMSO--d6) δ12.57(s,1H),8.69–8.59(m,1H),8.22(dd,J=7.8,1.3Hz,1H),7.96(dd,J=7.8,1.3Hz,1H),7.84–7.79(m,2H),7.7 4(td,J=7.8,1.3Hz,1H), 7.64(tt,J=7.8,1.3Hz,2H), 7.56(td,J=7.8,1.3Hz,1H), 7.41(dd,J=7.8,1.3Hz,1H), 7.30(dd,J=7.8,1.3Hz,1H).
[0047] Example 4: TM-4
[0048]
[0049] The synthesis method is similar to that of TM-1, except that the first step uses 3-chloro-4-cyanopyridine instead of 4-cyanopyridine, and the final step yields 55% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.57(s,1H),8.85(d,J=0.6Hz,1H),8.70(d,J=5.0Hz, 1H),8.20(dd,J=7.6,1.3Hz,1H),7.96(dd,J=7.6,1.3Hz,1H),7.77(dd,J=5.0,0 .6Hz,1H),7.74(td,J=7.6,1.3Hz,1H),7.64(tdd,J=7.6,3.8,1.3Hz,3H),7.55( td, J=7.6, 1.3Hz, 1H), 7.40 (dd, J=7.6, 1.3Hz, 1H), 7.30 (dd, J=7.6, 1.3Hz, 1H).
[0050] Example 5: TM-5
[0051]
[0052] The synthesis method is similar to that of TM-1, except that the first step uses 2-fluoro-4-cyanopyridine instead of 4-cyanopyridine, and the final step yields 62% in a white solid. 1H NMR (400MHz, DMSO-d6) δ12.57(s,1H),8.46(d,J=5.1Hz,1H),8.21(dd,J=7.6,1.4Hz,1H),7.96(dd,J=7.6,1.4Hz,1H),7.78–7.7 0(m,2H),7.68–7.60(m,2H),7.56(td,J=7.6,1.4Hz,1H),7.51(s,1H),7.41(dd,J=7.6,1.4Hz,1H),7.30(dd,J=7.6,1.4Hz,1H).
[0053] Example 6: TM-6
[0054]
[0055] The synthesis method is similar to that of TM-1, except that 4-cyanopyridine is replaced with 2-methyl-4-cyanopyridine in the first step, and the yield of the last step is 65%, a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.56(s,1H),8.63(dd,J=5.2,0.9Hz,1H),8.20(dd,J=7.8,1.4Hz,1H),7.96(dd,J=7.8,1.4Hz,1H),7.73( td,J=7.8,1.4Hz,1H),7.68–7.60(m,3H),7.60–7.52(m,2H),7.40(dd,J=7.8,1.4Hz,1H),7.29(dd,J=7.8,1.4Hz,1H),2.55(s,3H).
[0056] Example 7: TM-7
[0057]
[0058] The synthesis method is similar to that of TM-1, except that 4-cyanopyridine is replaced with 2-methoxy-4-cyanopyridine in the first step, and the yield of the last step is 52%, a white solid. 1H NMR (400MHz, DMSO-d6) δ12.54(s,1H),8.34(d,J=5.3Hz,1H),8.19(dd,J=7.8,1.4Hz,1H),7.96(dd,J=7.8,1.4Hz,1H),7.73(td,J=7.8,1.4Hz,1 H),7.63(td,J=7.8,1.4Hz,2H),7.56(td,J=7.8,1.4Hz,1H),7.42–7.37(m,2H),7.29(dd,J=7.8,1.4Hz,1H),7.12(t,J=1.4Hz,1H),3.90(s,3H).
[0059] Example 8: TM-8
[0060]
[0061] The synthesis method is similar to that of TM-1, except that 4-cyanopyridine is replaced with 2,6-dimethyl-4-cyanopyridine in the first step, and the yield of the last step is 63%, a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.55(s,1H),8.19(dd,J=7.6,1.4Hz,1H),7.96(dd,J=7.6,1.4Hz,1H),7.73(td,J=7.6,1.4Hz,1H),7.63(tdd, J=7.6,2.7,1.4Hz,2H),7.56(td,J=7.6,1.4Hz,1H),7.45(s,2H),7.40(dd,J=7.6,1.4Hz,1H),7.29(dd,J=7.6,1.4Hz,1H),2.49(s,6H).
[0062] Example 9: TM-9
[0063]
[0064] The synthesis method is similar to that of TM-1, except that the first step uses quinoline-4-carboxynitrile instead of 4-cyanopyridine, and the final step yields 53% in a white solid. 1H NMR(400MHz,DMSO-d6)δ12.56(s,1H),9.06(d,J=4.4Hz,1H),8.42(dd,J=8.6,1.4Hz,1H),8 .25(dd,J=7.8,1.4Hz,1H),8.14(dd,J=8.6,1.4Hz,1H),8.00(dd,J=7.8,1.4Hz,1H),7.96(d ,J=4.4Hz,1H),7.87(ddd,J=8.6,6.8,1.4Hz,1H),7.76(td,J=7.5,1.4Hz,1H),7.72–7.64(m ,4H),7.61(td,J=7.5,1.4Hz,1H),7.43(dd,J=7.5,1.4Hz,1H),7.36(dd,J=7.5,1.4Hz,1H).
[0065] Example 10: TM-10
[0066]
[0067] The synthesis method is similar to that of TM-1, except that the first step uses 3-cyanoquinoline instead of 4-cyanopyridine, and the final step yields 51% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.57(s,1H),9.27(d,J=2.2Hz,1H),8.90(dd,J=2.2,0.8Hz,1H),8.26( dd,J=7.8,1.5Hz,1H),8.17(dd,J=8.4,1.5Hz,1H),8.11(dd,J=8.4,1.1Hz,1H),8.00(dd,J=7.8 ,1.5Hz,1H),7.90(ddd,J=8.4,6.9,1.5Hz,1H),7.74(qd,J=7.8,1.5Hz,2H),7.66(td,J=7.8,1. 5Hz, 2H), 7.59 (td, J=7.8, 1.5Hz, 1H), 7.43 (dd, J=7.8, 1.5Hz, 1H), 7.32 (dd, J=7.8, 1.5Hz, 1H).
[0068] Example 11: TM-11
[0069]
[0070] The synthesis method is similar to that of TM-1, except that 4-cyanopyrimidine is used instead of 4-cyanopyridine in the first step, and the yield of the last step is 66%, a white solid. 1H NMR (400MHz, DMSO-d6) δ12.59 (s, 1H), 9.38 (d, J = 1.4Hz, 1H), 9.07 (d, J = 5.1Hz, 1H),8.21(dd,J=7.8,1.4Hz,1H),7.96(dd,J=7.8,1.4Hz,1H),7.90(dd,J=5.1,1 .4Hz,1H),7.74(td,J=7.8,1.4Hz,1H),7.64(tdd,J=7.8,2.5,1.4Hz,2H),7.56( td, J=7.8, 1.4Hz, 1H), 7.40 (dd, J=7.8, 1.4Hz, 1H), 7.30 (dd, J=7.8, 1.4Hz, 1H).
[0071] Example 12: TM-12
[0072]
[0073] The synthesis method is similar to that of TM-1, except that 3-cyanopyridine is used instead of 4-cyanopyridine in the first step, and the yield in the last step is 52%, a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.56(s,1H),9.00(s,1H),8.75(s,1H),8.20(d,J=7.5Hz,2H),7.97(d,J=7.5Hz,1H), 7.72(t,J=7.5Hz,1H),7.63(t,J=7.5Hz,2H),7.60–7.52(m,2H),7.40(d,J=7.5Hz,1H),7.29(d,J=7.5Hz,1H).
[0074] Example 13: TM-13
[0075]
[0076] The synthesis method is similar to that of TM-1, except that 2-cyanopyridine is used instead of 4-cyanopyridine in the first step, and the yield of the last step is 50%, a white solid. 1H NMR (400MHz, DMSO-d6) δ12.56(s,1H),8.76–8.70(m,1H),8.20(d,J=7.6Hz,1H),8.03–7.93(m,2H),7.86(dd,J=8.0,0. 8Hz,1H),7.72(t,J=7.6Hz,1H),7.63(t,J=7.6Hz,2H),7.60–7.52(m,2H),7.39(d,J=7.6Hz,1H),7.30(d,J=7.6Hz,1H).
[0077] Example 14: TM-14
[0078]
[0079] The synthesis method is similar to that of TM-1, except that the first step uses p-fluorobenzonitrile instead of 4-cyanopyridine, and the final step yields 55% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.54(s,1H),8.18(d,J=7.7Hz,1H),7.96(d,J=7.7Hz,1H),7.94–7.86(m,2H),7 .76–7.67(m,1H),7.68–7.59(m,2H),7.55(t,J=7.7Hz,1H),7.38(t,J=8.9Hz,3H),7.28(d,J=7.7Hz,1H).
[0080] Example 15: TM-15
[0081]
[0082] The synthesis method is similar to that of TM-1, except that the first step uses p-trifluoromethylbenzonitrile instead of 4-cyanopyridine, and the final step yields 61% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.56(s,1H),8.20(d,J=7.5Hz,1H),8.06(d,J=8.1Hz,2H),7.97(d,J=7.5Hz,1H),7.90(d,J=8.1 Hz, 2H), 7.72 (t, J = 7.5Hz, 1H), 7.63 (t, J = 7.5Hz, 2H), 7.55 (t, J = 7.5Hz, 1H), 7.40 (d, J = 7.5Hz, 1H), 7.29 (d, J = 7.5Hz, 1H).
[0083] Example 16: TM-16
[0084]
[0085] The synthesis method is similar to that of TM-1, except that the first step uses p-chlorobenzonitrile instead of 4-cyanopyridine, and the final step yields 61% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.55(s,1H),8.18(d,J=7.8Hz,1H),7.96(d,J=7.8Hz,1H),7.86(d,J=8.7Hz,2H),7 .72(t,J=7.8Hz,1H),7.66–7.59(m,4H),7.55(t,J=7.8Hz,1H),7.39(d,J=7.8Hz,1H),7.28(d,J=7.8Hz,1H).
[0086] Example 17: TM-17
[0087]
[0088] The synthesis method is similar to that of TM-1, except that the first step uses p-bromobenzonitrile instead of 4-cyanopyridine, and the final step yields 51% in a white solid. 1 H NMR (400MHz, DMSO-d6) δ12.54(s,1H),8.18(d,J=7.5Hz,1H),7.95(d,J=7.5Hz,1H),7.79(d,J=8.5Hz,2H),7.74(d,J=8.5 Hz, 2H), 7.70 (d, J = 7.5Hz, 1H), 7.62 (t, J = 7.5Hz, 2H), 7.55 (t, J = 7.5Hz, 1H), 7.39 (d, J = 7.5Hz, 1H), 7.28 (d, J = 7.5Hz, 1H).
[0089] Example 18: TM-18
[0090]
[0091] The synthesis method is similar to that of TM-1, except that 4-methoxycyanobenzene is used instead of 4-cyanopyridine in the first step, and the yield of the last step is 51%, a white solid. 1H NMR (400MHz, DMSO-d6) δ12.53(s,1H),8.17(dd,J=7.6,1.3Hz,1H),7.97(dd,J=7.6,1.3Hz,1H),7.83–7.75(m,2H),7.70(td,J=7.6,1.3Hz,1 H),7.65–7.58(m,2H),7.55(td,J=7.6,1.3Hz,1H),7.38(dd,J=7.6,1.3Hz,1H),7.27(dd,J=7.6,1.3Hz,1H),7.10–7.02(m,2H),3.81(s,3H).
[0092] Example 19: TM-19
[0093]
[0094] The synthesis method is similar to that of TM-1, except that the first step uses p-toluenenitrile instead of 4-cyanopyridine, and the final step yields 60% of the product as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.52 (s, 1H), 8.18 (d, J = 7.6 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.71 (t, J = 7.6 Hz, 1H), 7.67–7.59 (m, 2H), 7.55 (t, J = 7.6 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.33 (d, J = 8.0 Hz, 2H), 7.28 (d, J = 7.6 Hz, 1H), 2.36 (s, 3H).
[0095] Example 20: TM-20
[0096]
[0097] The synthesis method is similar to that of TM-1, except that 3-bromobenzonitrile is used instead of 4-cyanopyridine in the first step, and the final step yields 60% of the product as a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.19 (d, J = 7.6 Hz, 1H), 8.00–7.93 (m, 2H), 7.86 (d, J = 7.6 Hz, 1H), 7.81–7.75 (m, 1H), 7.72 (td, J = 7.6, 1.2 Hz, 1H), 7.67–7.59 (m, 2H), 7.56 (td, J = 7.6, 1.2 Hz, 1H), 7.49 (t, J = 7.6 Hz, 1H), 7.40 (d, J = 7.6 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H).
[0098] Example 21: TM-21
[0099]
[0100] The synthesis method is similar to that of TM-1, except that 2-cyanofuran is used instead of 4-cyanopyridine in the first step, and the final step yields 58% in a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.56 (s, 1H), 8.15 (d, J = 7.5 Hz, 1H), 7.94 (d, J = 9.2 Hz, 2H), 7.75–7.67 (m, 1H), 7.65–7.58 (m, 2H), 7.58–7.50 (m, 1H), 7.38 (d, J = 7.5 Hz, 1H), 7.27 (d, J = 7.5 Hz, 1H), 7.06 (d, J = 3.4 Hz, 1H), 6.77–6.67 (m, 1H).
[0101] Example 22: TM-22
[0102]
[0103] The synthesis method is similar to that of TM-1, except that 2-cyanothiophene is used instead of 4-cyanopyridine in the first step, and the final step yields 58% in a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.54 (s, ¹H), 8.16 (d, J = 7.5 Hz, ¹H), 7.96 (d, J = 7.5 Hz, ¹H), 7.84 (d, J = 4.9 Hz, ¹H), 7.71 (t, J = 7.5 Hz, ¹H), 7.67–7.58 (m, ³H), 7.54 (t, J = 7.5 Hz, ¹H), 7.38 (d, J = 7.5 Hz, ¹H), 7.28 (d, J = 7.5 Hz, ¹H), 7.23 (t, J = 4.9 Hz, ¹H).
[0104] Example 23: TM-23
[0105]
[0106] The synthesis method is similar to that of TM-1, except that 3-cyanothiophene is used instead of 4-cyanopyridine in the first step, and the final step yields 58% in a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.53 (s, ¹H), 8.16 (d, J = 7.6 Hz, ¹H), 8.10 (d, J = 2.8 Hz, ¹H), 7.95 (d, J = 7.6 Hz, ¹H), 7.74 (dd, J = 5.0, 2.8 Hz, ¹H), 7.70 (t, J = 7.6 Hz, 1H), 7.62 (t, J = 7.6 Hz, 2H), 7.54 (t, J = 7.6 Hz, 1H), 7.45 (d, J = 5.0 Hz, 1H), 7.38 (d, J = 7.6 Hz, 1H), 7.27 (d, J = 7.6 Hz, 1H).
[0107] Example 24: TM-24
[0108]
[0109] The synthesis method is similar to that of TM-1, except that the first step uses quinoline-6-carboxynitrile instead of 4-cyanopyridine, and the final step yields 48% in a white solid. 1H NMR (400MHz, DMSO-d6) δ12.57(s,1H),9.00(dd,J=4.2,1.7Hz,1H),8.57(d,J=1.7 Hz,1H),8.53(dd,J=8.3,1.7Hz,1H),8.25(dd,J=7.6,1.4Hz,1H),8.20–8.11(m,2H ),8.00(dd,J=7.6,1.4Hz,1H),7.73(dd,J=7.6,1.4Hz,1H),7.69–7.62(m,3H),7.5 9(td,J=7.6,1.4Hz,1H), 7.42(dd,J=7.6,1.4Hz,1H), 7.32(dd,J=7.6,1.4Hz,1H).
[0110] Example 25: TM-25
[0111]
[0112] The synthesis method is similar to that of TM-1, except that 4-methoxy-1-naphthoonitrile is used instead of 4-cyanopyridine in the first step, and the final step yields 36% in a white solid. ¹H NMR (400 MHz, DMSO-d6) δ 12.55 (s, 1H), 8.60–8.45 (m, 1H), 8.29–8.24 (m, 1H), 8.22 (dd, J = 7.5, 1.4 Hz, 1H), 8.07–7.96 (m, 2H), 7.73 (td, J = 7.5, 1.4 Hz, 1H), 7.69–7.54 (m, 5H), 7.41 (dd, J = 7.5, 1.4 Hz, 1H), 7.34 (dd, J = 7.5, 1.4 Hz, 1H), 7.10 (d, J = 8.3 Hz, 1H), 4.05 (s, 3H).
[0113] Pharmacological experiments:
[0114] Experimental Example 1: In vitro inhibitory activity of the target compound against hURAT1
[0115] method:
[0116] HEK-293T cells stably expressing hURAT1 were cultured (DMEM medium + 10% fetal bovine serum + 500 μg / mL LG418 + 1% P / S). Cells were seeded into 96-well cell culture plates and cultured for 12–24 hours. The compound was prepared as a 10 mM stock solution using DMSO, then diluted to 1 mM with buffer, and further serially diluted 4-fold. Once the cells adhered to the plates in the 96-well plates, the culture could proceed. 14 C-uric acid uptake assay in hURAT1-stable cells. 50 μL of the corresponding compound and 0.1 Ci / mL were added to each well. 14 After incubating C-uric acid solution at 37°C for 5 minutes, immediately add 150 μL of ice-cold buffer to terminate absorption. Add 50 μL / well of lysis buffer to all wells and shake at 900 rpm for 5 minutes. Add 150 μL / well of Microsint 40 scintillation solution and shake at 900 rpm for 5 minutes. Radioactivity was measured using a MicroBetaTrilux instrument (PerkinElmer) and the data were analyzed using XL-fit software.
[0117] result:
[0118] The inhibition rates of the above compounds against hURAT1 at a concentration of 10 μM were determined; the IC50 values of the compounds with better inhibitory activity were determined and calculated. 50 The values are shown in Table 1.
[0119] Table 1. Inhibitory effects of compounds on hURAT1
[0120]
[0121] *: Inhibition rate was measured at 10 μM;
[0122] ND: Not Determined.
Claims
1. A biphenyl carboxylic acid compound represented by the following general formula (I) and its physiologically acceptable salt, (I) in, Ar is selected from substituted pyridyl, substituted or unsubstituted quinolinyl, substituted or unsubstituted naphthyl, substituted or unsubstituted pyrimidinyl, and substituted or unsubstituted furanyl; the substituent is a monosubstituted or polysubstituted group, each independently selected from hydrogen, halogen, C 1- C3 alkyl, C 1- C3 alkoxy group.
2. The compound according to claim 1 and its physiologically acceptable salt, characterized in that, The compounds described are those represented by general formula (IA) and their physiologically acceptable salts: (IA) in, R1 and R2 are independently selected from halogens and C. 1- C3 alkyl, C 1- C3 alkoxy group.
3. The compound according to claim 1 and its physiologically acceptable salt, characterized in that, The compounds described are those represented by general formula (IB) and their physiologically acceptable salts: (IB) in, R3 is selected from hydrogen, halogens, and C. 1- C3 alkyl, C 1- C3 alkoxy group.
4. A compound having the following structure and its physiologically acceptable salt, characterized in that, The compound is selected from:
5. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises an effective dose of any compound as described in any one of claims 1 to 4, a physiologically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof.
6. The pharmaceutical composition according to claim 5, characterized in that, The pharmaceutical composition is selected from tablets, capsules, pills, and injections.
7. Use of the compound according to any one of claims 1 to 4 and its physiologically acceptable salt in the preparation of urate transporter 1 inhibitors.
8. The use of the compound of any one of claims 1 to 4 or a physiologically acceptable salt thereof in the preparation of a medicament for the prevention and / or treatment of URAT1-related diseases, wherein the diseases are selected from hyperuricemia and gout.
